New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Aligos Therapeutics, Inc. (ALGS) vs VistaGen Therapeutics, Inc. (VTGN)
- Aligos Therapeutics, Inc. ALGS 1.22 −2.40%
- VistaGen Therapeutics, Inc. VTGN 0.16 −15.79%
Aligos Therapeutics, Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. Aligos Therapeutics, Inc. and VistaGen Therapeutics, Inc. are of similar size ($8.8M and $8.6M). Aligos Therapeutics, Inc. grew revenue faster over the last twelve months: 1,171.6% against 230.2%. Aligos Therapeutics, Inc. has the higher net margin (−197.0% vs −2,475.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Aligos Therapeutics, Inc. leads on 9 and VistaGen Therapeutics, Inc. on 6.
Valuation
Profitability
| Metric | ALGS | VTGN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (215.55%) | (2,543.22%) | 0.00% |
| Net margin | (197.01%) | (2,475.56%) | 0.00% |
| Free cash flow margin | (204.07%) | (2,549.39%) | 0.00% |
| Return on equity | (159.46%) | (144.95%) | (51.58%) |
| Return on assets | (84.46%) | (112.97%) | (45.91%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack